Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School gives an overview of his discussion, Novel Treatment Options for Neuroendocrine Tumors, which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.
TELESTAR Results and Telotristat Ethyl for Advanced Neuroendocrine Tumors
